Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile ...
The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...
AMD is the leading cause of central vision loss in the elderly, affecting 200 million people worldwide. AMD's pathogenesis is complex and involves the dysregulation of iron homeostasis, leading to an ...
Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 ...
Evidence Supporting ACLF Pipeline Strategic Development New trials ... will be conducted in healthy volunteers, with clinical data readout anticipated by late 2025. With the readout of UNVEIL-IT® ...
The E.mbrace study is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...
In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the other AI ...
LUND, SE / ACCESS Newswire / February 6, 2025 / Alligator Bioscience (STO:ATORX) FDA feedback validates the clinical ...
The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback